AGCO to Present at the Bernstein Operational Decisions Conference

AGCO to Present at the Bernstein Operational Decisions Conference

DULUTH, Ga.–(BUSINESS WIRE)–
AGCO, Your Agriculture Company (NYSE:AGCO), a worldwide manufacturer and distributor of agricultural equipment and infrastructure, announced today that it will participate in the Bernstein Operational Decisions Conference on Monday, November 16, 2020. The conference will include a presentation by Andy Beck, AGCO’s Senior Vice President and Chief Financial Officer at 1:30 p.m. E.T. Investors may listen to a live webcast of the presentation by accessing the webcast button in the “Investors” section of the Company’s website at http://www.agcocorp.com/company/investors.aspx. The webcast will also be archived immediately afterwards.

About AGCO

AGCO (NYSE:AGCO) is a global leader in the design, manufacture and distribution of agricultural solutions and delivers high-tech solutions for farmers feeding the world through its full line of equipment and related services. AGCO products are sold through five core brands, Challenger®, Fendt®, GSI®, Massey Ferguson® and Valtra®, supported by Fuse® smart farming solutions. Founded in 1990 and headquartered in Duluth, Georgia, USA, AGCO had net sales of $9.0 billion in 2019. For more information, visit http://www.AGCOcorp.com. For company news, information and events, please follow us on Twitter: @AGCOCorp. For financial news on Twitter, please follow the hashtag #AGCOIR.

Please visit our website at www.agcocorp.com

Greg Peterson

Vice President, Investor Relations

(770) 232-8229

[email protected]

KEYWORDS: Georgia United States North America

INDUSTRY KEYWORDS: Agriculture Natural Resources

MEDIA:

Logo
Logo

UROVANT ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of UROV and Encourages Investors to Contact the Firm

NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Urovant Sciences Ltd. (NASDAQ: UROV) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Sumitovant Biopharma Ltd.

Click here to learn more and participate in the action.

On November 12, 2020, Urovant announced that it had signed an agreement to be acquired by Sumitovant for approximately $584 million. Pursuant to the merger agreement, Urovant stockholders will receive $16.25 in cash for each share of Urovant common stock owned. The deal is scheduled to close in the first quarter of 2021.

Bragar Eagel & Squire is concerned that Urovant’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Urovant’s stockholders.

If you own shares of Urovant and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato or Alexandra Raymond by email at [email protected] or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.
Melissa Fortunato, Esq.
Alexandra Raymond, Esq.
[email protected]
www.bespc.com



SHAREHOLDER ALERT: WeissLaw LLP Investigates Urovant Sciences Ltd.

PR Newswire

NEW YORK, Nov. 13, 2020 /PRNewswire/ — WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Urovant Sciences Ltd. (“UROV” or the “Company”) (NASDAQ: UROV) in connection with the proposed interested-party acquisition of the Company by Sumitovant Biopharma Ltd. (“Sumitovant”), UROV’s majority shareholder that currently owns 72% of the Company’s outstanding common shares. Under the terms of the acquisition agreement, the Company’s shareholders will receive only $16.25 in cash for each share of UROV common stock that they own.


If you own UROV shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:


https://www.weisslawllp.com/urov/


Or please contact:



Joshua Rubin, Esq.

WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
[email protected]

WeissLaw is investigating whether (i) the special committee of UROV’s board was truly independent and acted to maximize shareholder value in agreeing to the proposed transaction, (ii) the $16.25 per share merger consideration adequately compensates UROV’s minority shareholders, (iii) the special committee was fully informed as to the valuation of the proposed acquisition of the Company, and (iv) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed. These issues are of particular concern given the influence and control Sumitovant wields over UROV by virtue of its ownership of a majority of the Company’s outstanding shares. Moreover, the per-share merger consideration is significantly lower than an analyst price target of $28.00, suggesting the special committee may have agreed to an undervalued deal at the behest of Sumitovant.

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-urovant-sciences-ltd-301172926.html

SOURCE WeissLaw LLP

PCT LTD Announces Receipt of New $300K Conventional Convertible Funding from RB Capital Partners, Inc. and Updates Status of OTCQB Application

PCT LTD Announces Receipt of New $300K Conventional Convertible Funding from RB Capital Partners, Inc. and Updates Status of OTCQB Application

LITTLE RIVER, S.C.–(BUSINESS WIRE)–
PCT LTD (OTC Pink: PCTL) announces that, on Wednesday, November 11, 2020 the Company executed an additional 6-month term conventional convertible note with RB Capital Partners, Inc. in the amount of $300,000 with a conversion price of $0.15/share of PCT LTD’s common stock (par value $0.001) and a five percent (5%), fixed annual interest rate. Much of this funding is dedicated to the purchase of inventory needed to finish assembly of equipment to fulfill current orders, as well as prepare additional equipment for impending sales that are in the pipeline now. In addition, a portion of this funding is being used by PCT LTD to settle the last of the remaining prior year convertible debt which will allow the Company to finalize the move to OTCQB.

About PCT LTD:

PCT LTD (“PCTL”) focuses its business on acquiring, developing and providing sustainable, environmentally safe disinfecting, cleaning and tracking technologies. The company acquires and holds rights to innovative products and technologies, which are commercialized through its wholly-owned operating subsidiary, Paradigm Convergence Technologies Corporation (PCT Corp). Currently trading on OTC:PINK, “PCTL” is actively engaged in applying for listing its common stock to the OTC QB market. The Company established entry into its target markets with commercially viable products in the United States and now continues to gain market share in the U.S. and U.K.

ADDITIONAL NEWS AND CORPORATE UPDATES:

PCTL would like to warn its stockholders and potential investors that material corporate information regarding sales, areas of business and other corporate updates will only be made through press releases or filings with the SEC. PCTL does not utilize social media, chatrooms or other online sources to disclose material information. The public should only rely on official press releases and corporate filings for accurate and up to date information regarding PCTL.

Forward-Looking Statements:

This press release contains “forward-looking statements” as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21B of the Securities Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements.”

Such statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Such statements involve risks and uncertainties, including but not limited to: the actual results of PCTL’s ability to order and receive inventory in a timely manner; PCTL’s continued installation of equipment; subsequent installations of PCTL’s Annihilyzer Infection Control Systems and other larger-volume equipment; PCTL’s ability to raise sufficient funds to satisfy its working capital requirements; the ability of PCTL to execute its business plan; the anticipated results of business contracts with regard to revenue; and any other effects resulting from the information disclosed above; risks and effects of legal and administrative proceedings and government regulation; future financial and operational results; competition; general economic conditions; and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements PCTL makes in this press release include market conditions and those set forth in reports or documents it files from time to time with the SEC. PCTL undertakes no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Gary Grieco, CEO and Chairman, PCT LTD

(843) 390-7900 Office

(843) 390-2347 Fax

www.para-con.com

www.pctcorphealth.com

www.survivalyte.com

Rich Inza, Investor Relations (RMJ Consulting, LLC)

(843) 491-4611

[email protected]

Dave Donlin, Investor Relations (Cervelle Group)

(407) 405-8142

KEYWORDS: United States North America South Carolina

INDUSTRY KEYWORDS: Health Communications Social Media Environment Search Engine Optimization General Health Public Relations/Investor Relations

MEDIA:

Logo
Logo

BNY Mellon Alcentra Global Multi-Strategy Credit Fund, Inc. Announces Final Results of Initial Quarterly Tender Offer

BNY Mellon Alcentra Global Multi-Strategy Credit Fund, Inc. Announces Final Results of Initial Quarterly Tender Offer

NEW YORK–(BUSINESS WIRE)–
BNY Mellon Alcentra Global Multi-Strategy Credit Fund, Inc. (the “Fund”) today announced the final results of its initial quarterly tender offer (the “Tender Offer”) for up to 2.5% of the Fund’s issued and outstanding shares of common stock (the “Shares”).

The Tender Offer, which expired at 5:00 p.m. Eastern time on November 12, 2020, was oversubscribed.

Therefore, in accordance with the terms and conditions of the Tender Offer, the Fund will purchase Shares from all tendering shareholders on a pro rata basis, after disregarding fractions, based on the number of Shares properly tendered (“Pro-Ration Factor”). The final results of the Tender Offer are provided in the table below.

Number of Shares

Tendered

Number of Tendered

Shares to Be

Purchased

Pro- Ration Factor

Purchase Price*

205,585

66,325

0.32261595

$94.81

*Purchase Price is equal to 100% of the Fund’s net asset value per Share as of September 30, 2020.

If you have questions about the Tender Offer and hold Shares through a broker or other nominee holder, you can call your broker or other nominee holder directly. You may also call Georgeson LLC, the Fund’s Tender Offer information agent, toll free at (877) 278-9670, with any questions.

This announcement is for informational purposes only and is not a recommendation, an offer to purchase or a solicitation of an offer to sell Shares. The terms and conditions of the Tender Offer were set forth in the Fund’s Offer to Purchase, the related Letter of Transmittal and other related documents. The Fund filed with the Securities and Exchange Commission (the “SEC”) a tender offer statement on Schedule TO and related exhibits, including an Offer to Purchase, a related Letter of Transmittal and other related documents (the “Offer Documents”). Shareholders may obtain copies of the Offer Documents, without charge, by contacting Georgeson LLC, the Fund’s Tender Offer information agent, toll free at (877) 278-9670. Shareholders can also obtain the Offer Documents free of charge on the SEC’s website at www.sec.gov.

*****

BNY Mellon Investment Adviser, Inc., the investment adviser for the Fund, is part of BNY Mellon Investment Management. BNY Mellon Investment Management is one of the world’s leading investment management organizations and one of the top U.S. wealth managers, with US $2.0 trillion in assets under management as of September 30, 2020. BNY Mellon Investment Management encompasses BNY Mellon’s affiliated investment management firms, wealth management organization and global distribution companies. Through an investor-first approach, BNY Mellon Investment Management brings to clients the best of both worlds: specialist expertise from eight world-class investment firms offering solutions across every major asset class, backed by the strength, stability, and global presence of The Bank of New York Mellon Corporation (NYSE: BK), one of the world’s most trusted investment partners, which has US $38.6 trillion in assets under custody and/or administration as of September 30, 2020.

BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation and may also be used as a generic term to reference the Corporation as a whole or its various subsidiaries generally. Additional information on BNY Mellon Investment Management is available on www.im.bnymellon.com. BNY Mellon Investment Management’s website is intended to allow investors public access to information regarding the Fund and does not, and is not intended to, incorporate the website in this release.

The Fund’s investment returns and principal values will fluctuate so that an investor’s shares may be worth more or less than the original cost. There is no assurance that the Fund will achieve its investment objective.

For Press Inquiries:

BNY Mellon Investment Adviser, Inc.

Benjamin Tanner

(212) 635-8676

For Other Inquiries:

BNY Mellon Securities Corporation

The National Marketing Desk

240 Greenwich Street

New York, New York 10286

1-800-334-6899

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo

Shareholder Alert: Robbins LLP Is Investigating Officers and Directors of Eastman Kodak Co. (KODK)

Shareholder Alert: Robbins LLP Is Investigating Officers and Directors of Eastman Kodak Co. (KODK)

SAN DIEGO & ROCHESTER, N.Y.–(BUSINESS WIRE)–
Shareholder rights law firm Robbins LLP is investigating the officers and directors of Eastman Kodak Co. (NYSE:KODK) for possible breaches of fiduciary duties. Eastman Kodak is a technology company that provides hardware, software, and services to customers in commercial print, packaging, publishing, manufacturing, and entertainment.

If you suffered a loss due to Kodak’s misconduct, we encourage you to contact us.

Eastman Kodak Co. (KODK) Admits to Having Deficient Internal Controls

The Financial Times recently reported that in July Kodak gave five former executives stock worth millions of dollars in exchange for stock options they did not own, which resulted in former officers and employees exercising 300,000 options they had previously forfeited. According to Kodak’s chief financial officer, Kodak’s “controls were inadequate with regard to the timely input and verification of master data updates for equity grants and therefore, resulted in errors or misstatements in employee equity account balances.” Kodak took a $5.1 million expense in the third quarter related to the options.

Kodak (KODK) Shareholders Have Legal Options

Contact us to learn more:

Lauren Levi

(800) 350-6003

[email protected]

Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Kodak settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Lauren Levi

Robbins LLP

5040 Shoreham Place

San Diego, CA 92122

[email protected]

(800) 350-6003

www.robbinsllp.com

KEYWORDS: United States North America California New York

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo

ROSEN, LEADING INVESTOR COUNSEL, Reminds Celsion Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – CLSN

NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the “Class Period”), of the important December 29, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Celsion investors under the federal securities laws.

To join the Celsion class action, go to http://www.rosenlegal.com/cases-register-1978.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) defendants had significantly overstated the efficacy of ThermoDox; (2) the foregoing significantly diminished the approval and commercialization prospects for ThermoDox; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 29, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1978.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        [email protected]
        [email protected]
        www.rosenlegal.com



Agenus and Dr. Steven O’Day to Participate in Webcast Hosted by William Blair on AGEN1181 and SITC Data

LEXINGTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) —  Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Steven O’Day, Executive Director of the John Wayne Cancer Institute, Dr. Jennifer Buell, President and COO of Agenus, and Dr. Dhan Chand, Scientific Director Head of Drug Discovery at Agenus, will participate in a webcast hosted by Dr. Matt Phipps of William Blair on Monday, November 16, 2020 at 10:00 a.m. ET.

Dr. Steven O’Day will review data of AGEN1181 from its ongoing Ph1 dose escalation trial and discuss the initial responses, particularly those in patients with microsatellite stable disease, and how to place these data in context with other CTLA-4 antibodies. He will also discuss the potential implications of demonstrated Treg depletion with AGEN1181.

Dr. Jennifer Buell and Dr. Dhan Chand of Agenus will be available to discuss the next steps for AGEN1181 and indications selected for expansion. They will also discuss data from other programs presented at SITC, including first clinical data for AGEN2373, a CD137 agonist, the demonstrated importance of Fc-enhancement for TIGIT, and preclinical data for AgenT-797, AgenTus’ iNKT cell therapy, which recently entered the clinic for COVID-19.

Registration for the webinar can be done in advance at https://williamblair.zoom.us/webinar/register/WN_b0mxF_6yTWaC3bOTmfiTig.

A replay will be available after the call on the Events & Presentations page of the Agenus website at https://investor.agenusbio.com/events-and-presentations.


About Agenus


Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body’s immune system to fight cancer. The Company’s vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.


Forward-Looking Statements


This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the potential and anticipated next steps for Agenus’ AGEN1181, AGEN2373, anti-TIGIT, and AgenT-797, as well as the rest of its other pipeline assets. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.


Contact:


Agenus Inc.

Caroline Bafundo
212-994-8209
[email protected] 



Tenneco Announces Pricing of Notes Offering

PR Newswire

LAKE FOREST, Ill., Nov. 13, 2020 /PRNewswire/ — Tenneco Inc. (NYSE: TEN) (“Tenneco”) today announced that it has priced its previously announced notes offering (the “Offering”) and has agreed to issue and sell $500 million aggregate principal amount of 7.875% Senior Secured Notes due 2029 (the “Notes”). The Notes will be sold to investors at par. The Offering is expected to close on November 30, 2020, subject to customary closing conditions.

The Notes will be guaranteed by each of Tenneco’s subsidiaries that guarantees its credit facility and outstanding notes.  The Notes and the subsidiary guarantees will be secured by first priority security interests in substantially all of Tenneco’s and the subsidiary guarantors’ assets, subject to certain excluded assets, exceptions and permitted liens, which security interests will rank equally with the security interests securing its credit facility and outstanding secured notes.

Tenneco intends to use the net proceeds of the Offering to redeem all of its outstanding 4.875% Senior Secured Notes due 2022 (the “2022 Notes”), including the payment of premiums, accrued and unpaid interest and expenses related to such redemption. This press release shall not constitute a notice of redemption of the 2022 Notes.

The Notes and the related guarantees have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and may not be offered or sold in the United States or to U.S. persons absent registration or an applicable exemption from such registration requirements. Accordingly, the Notes and the related guarantees will be offered and sold only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act and to non-U.S. persons in offshore transactions outside the United States in accordance with Regulation S under the Securities Act.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Tenneco
Tenneco is one of the world’s leading designers, manufacturers and marketers of automotive products for original equipment and aftermarket customers, with 2019 revenues of $17.5 billion and approximately 78,000 team members working at more than 300 sites worldwide.  Through our four business groups, Motorparts, Ride Performance, Clean Air and Powertrain, Tenneco is driving advancements in global mobility by delivering technology solutions for diversified global markets, including light vehicle, commercial truck, off-highway, industrial, motorsport and the aftermarket. Visit www.tenneco.com to learn more.

Cautionary Note Regarding Forward-Looking Statements
The disclosures herein concerning the Offering and the use of net proceeds of the Offering include statements that are “forward looking” within the meaning of federal securities law. Consummation of the Offering is subject to a number of closing conditions and other factors. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements.

Investor inquiries

Linae Golla

847 482-5162
[email protected]

Rich Kwas
248-849-1340
[email protected]

Media inquiries

Bill Dawson

847 482-5807
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/tenneco-announces-pricing-of-notes-offering-301172940.html

SOURCE Tenneco Inc.

CORRECTING and REPLACING Ivory Celebrates World Kindness Day Through Initiative Aimed at Spreading Positivity

CORRECTING and REPLACING Ivory Celebrates World Kindness Day Through Initiative Aimed at Spreading Positivity

As pandemic leaves many older Americans feeling isolated, Ivory teams up with nonprofit organization Cool & Dope, to deliver care packs to seniors

CINCINNATI–(BUSINESS WIRE)–
Please replace the release with the following corrected version due to revisions in the ninth paragraph.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201113005485/en/

Ivory partnered with TV personality and mom of three, Catherine (Giudici) Lowe, and the nonprofit organization Cool & Dope's seven-year-old Chief Positivity Creator, Cavanaugh Bell, to support the elderly and make their days brighter with Ivory gentle care packs. In celebration of World Kindness Day, Ivory, known for providing a touch of love and kindness, is focused on spreading positivity with the launch of the brand’s Acts of Gentle Kindness initiative. (Photo: Business Wire)

Ivory partnered with TV personality and mom of three, Catherine (Giudici) Lowe, and the nonprofit organization Cool & Dope’s seven-year-old Chief Positivity Creator, Cavanaugh Bell, to support the elderly and make their days brighter with Ivory gentle care packs. In celebration of World Kindness Day, Ivory, known for providing a touch of love and kindness, is focused on spreading positivity with the launch of the brand’s Acts of Gentle Kindness initiative. (Photo: Business Wire)

The updated release reads:

IVORY CELEBRATES WORLD KINDNESS DAY THROUGH INITIATIVE AIMED AT SPREADING POSITIVITY

As pandemic leaves many older Americans feeling isolated, Ivory teams up with nonprofit organization Cool & Dope, to deliver care packs to seniors

This year has been especially challenging for both older Americans who have experienced isolation from family and friends due to the pandemic. In celebration of World Kindness Day, Ivory, known for providing a touch of love and kindness, is focused on spreading positivity with the launch of the brand’s Acts of Gentle Kindness initiative.

Ivory partnered with TV personality and mom of three, Catherine (Giudici) Lowe, and the nonprofit organization Cool & Dope’s seven-year-old Chief Positivity Creator, Cavanaugh Bell, to support the elderly and make their days brighter with Ivory gentle care packs.

Each Ivory gentle care pack contains an assortment of items such as Ivory Gentle Moisturizing Body Wash and Gentle Deodorant, designed to be gentle on skin through pure ingredients users will love and trust; socks and a cozy blanket to help them stay warm this winter, along with puzzles and brain games to add some fun and entertainment.

Families can create their own Ivory gentle care packs by using the following gifts for inspiration:

  • Personal care products designed to be gentle on all skin types:Ivory’s moisturizing body wash and Ivory’s gentle deodorant
  • Fun activities to help pass time: crossword or puzzle books, adult coloring books, or a deck of cards or other small games
  • Comfort items to help them feel safe and cozy:soft blanket or throw, fuzzy socks or slippers, soft towels or a robe
  • Special snacks and food for a little treat: homemade baked goods, favorite candy or snacks
  • Household supplies to help avoid extra trips to the store: toilet paper, hand soap, paper towels, cleaning supplies and sanitizers
  • Add a personal touch to fill your package with extra love and care: handwritten card or love notes, handmade gifts, artwork drawn by your children or framed photographs

With more than 54 million seniors above the age of 65 living in the U.S.1, COVID-19 has forced many of their family members to end visits to older parents and grandparents, as they are at high risk of contracting the illness. As a result, this has led older Americans to experience feelings of loneliness, which the CDC reports can be detrimental to a person’s health2.

“It’s truly amazing how a simple gesture can have such a positive impact on someone’s day,” said Catherine (Giudici) Lowe. “Seeing the smiles on the faces of the seniors we connected with and how happy it made my son, Samuel, really brought a smile to my face. I encourage parents to create an Ivory gentle care pack because it’s never too early to teach your children how to be kind to others, especially those in need.”

Catherine and Cavanaugh are encouraging families to get involved and spread kindness in their communities by creating and distributing their own care packs. With the help of Ivory, Cool & Dope can launch and maintain over 15 mobile pantries in and around Gaithersburg, MD through summer 2021, distributing additional care packs to older Americans.

“Everyone has the power to make a change and do good. That’s why I always say that anyone can have an impact – no matter their age,” said Cavanaugh Bell. “I hope moms and kids from all over the country make care packs for the senior citizens in their community so that our elderly know that they are loved.”

“This year, the world needs acts of kindness now more than ever as the pandemic has left many feeling isolated. For more than 100 years, Ivory has stood for passing down a touch of love and kindness from generation to generation. On World Kindness Day, we’re proud to create a way for young children to bring joy to older Americans living in their community,” said Freddy Bharucha, senior vice president, North America Personal Care, Procter & Gamble.

Share your Ivory gentle care packs on Instagram, Facebook or Pinterest with #IvoryKindness, and encourage your friends and family to do the same. To learn more about Ivory Acts of Gentle Kindness, visit ivory.com, and follow Ivory on Instagram @ivorysoap.

About Cool & Dope

Cool & Dope is a kid-led nonprofit, started by then six-year-old Cavanaugh Bell, who after being bullied and told that he was too young to volunteer, set out to prove to the world that anyone can have an impact. By speaking with federal, state, and local lawmakers, raising awareness about the effects of bullying, and spreading acts of kindness in his many kid-inspired community campaigns, Cavanaugh and his tribe of Positivity Creators are on a mission to end all bullying worldwide by 2030.

About Procter & Gamble

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands.

______________________

1Census.gov, “Older Population and Aging”. Accessed 13 November 2020. https://www.census.gov/topics/population/older-aging.html#:~:text=According%20to%20the%20U.S.%20Census,million%20on%20July%201%2C%202019

2Center for Disease Control, “Health Risks of Loneliness.” Accessed 13 November 2020. https://www.cdc.gov/aging/publications/features/lonely-older-adults.html#:~:text=Loneliness%20was%20associated%20with%20higher,risk%20of%20emergency%20department%20visits.

Procter & Gamble

Juwan Thompson

[email protected]

513-978-3107

Citizen Relations

Ashley Taveras

[email protected]

212-613-4961

KEYWORDS: United States North America Ohio Maryland

INDUSTRY KEYWORDS: Primary/Secondary Supermarket Infectious Diseases Education Foundation Women Seniors Cosmetics Retail Men Health Gay & Lesbian Family Consumer Home Goods Philanthropy Discount/Variety Public Relations/Investor Relations Parenting Children TV and Radio Communications General Entertainment Celebrity Entertainment Social Media General Health Other Philanthropy

MEDIA:

Photo
Photo
Ivory partnered with TV personality and mom of three, Catherine (Giudici) Lowe, and the nonprofit organization Cool & Dope’s seven-year-old Chief Positivity Creator, Cavanaugh Bell, to support the elderly and make their days brighter with Ivory gentle care packs. In celebration of World Kindness Day, Ivory, known for providing a touch of love and kindness, is focused on spreading positivity with the launch of the brand’s Acts of Gentle Kindness initiative. (Photo: Business Wire)
Photo
Photo
Ivory partnered with TV personality and mom of three, Catherine (Giudici) Lowe, and the nonprofit organization Cool & Dope’s seven-year-old Chief Positivity Creator, Cavanaugh Bell, to support the elderly and make their days brighter with Ivory gentle care packs. In celebration of World Kindness Day, Ivory, known for providing a touch of love and kindness, is focused on spreading positivity with the launch of the brand’s Acts of Gentle Kindness initiative. (Photo: Business Wire)
Logo
Logo
Photo
Photo
Ivory partnered with TV personality and mom of three, Catherine (Giudici) Lowe, and the nonprofit organization Cool & Dope’s seven-year-old Chief Positivity Creator, Cavanaugh Bell, to support the elderly and make their days brighter with Ivory gentle care packs. In celebration of World Kindness Day, Ivory, known for providing a touch of love and kindness, is focused on spreading positivity with the launch of the brand’s Acts of Gentle Kindness initiative. (Photo: Business Wire)